The latest price target for Viking Therapeutics (NASDAQ:VKTX) was reported by Morgan Stanley on September 12, 2024. The analyst firm set a price target for $105.00 expecting VKTX to rise to within 12 months (a possible 58.61% upside). 31 analyst firms have reported ratings in the last year.

The latest analyst rating for Viking Therapeutics (NASDAQ:VKTX) was provided by Morgan Stanley, and Viking Therapeutics reiterated their overweight rating.

The last upgrade for Viking Therapeutics Inc happened on May 16, 2024 when Raymond James raised their price target to $116. Raymond James previously had an outperform for Viking Therapeutics Inc.

There is no last downgrade for Viking Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viking Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viking Therapeutics was filed on September 12, 2024 so you should expect the next rating to be made available sometime around September 12, 2025.

While ratings are subjective and will change, the latest Viking Therapeutics (VKTX) rating was a reiterated with a price target of $105.00 to $105.00. The current price Viking Therapeutics (VKTX) is trading at is $66.20, which is out of the analyst’s predicted range.